349 related articles for article (PubMed ID: 28112819)
1. Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin.
Packiam VT; Johnson SC; Steinberg GD
Cancer; 2017 Feb; 123(3):390-400. PubMed ID: 28112819
[TBL] [Abstract][Full Text] [Related]
2. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
Saluja M; Gilling P
Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
[TBL] [Abstract][Full Text] [Related]
3. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
Herr HW; Dalbagni G
BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
[TBL] [Abstract][Full Text] [Related]
4. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
Steinberg RL; Thomas LJ; Nepple KG
Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
[TBL] [Abstract][Full Text] [Related]
5. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
[TBL] [Abstract][Full Text] [Related]
6. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
Prasad SM; Eyre S; Loughlin KR
Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
[TBL] [Abstract][Full Text] [Related]
7. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
Hassler MR; Shariat SF; Soria F
Curr Opin Urol; 2019 May; 29(3):239-246. PubMed ID: 30762670
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
9. Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
Crijnen J; De Reijke TM
Expert Opin Emerg Drugs; 2018 Jun; 23(2):135-147. PubMed ID: 29730950
[TBL] [Abstract][Full Text] [Related]
10. Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.
Khaled D; Taylor J; Holzbeierlein J
Urol Clin North Am; 2020 Feb; 47(1):119-128. PubMed ID: 31757295
[TBL] [Abstract][Full Text] [Related]
11. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
Barlow L; McKiernan J; Sawczuk I; Benson M
BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
[TBL] [Abstract][Full Text] [Related]
12. Immune therapies in non-muscle invasive bladder cancer.
Ho PL; Williams SB; Kamat AM
Curr Treat Options Oncol; 2015 Feb; 16(2):5. PubMed ID: 25757877
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
Poletajew S; Zapała P; Radziszewski P
Urol Int; 2017; 99(1):1-5. PubMed ID: 28601885
[TBL] [Abstract][Full Text] [Related]
14. Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure.
Becker REN; Kates MR; Bivalacqua TJ
Urol Clin North Am; 2020 Feb; 47(1):15-21. PubMed ID: 31757296
[TBL] [Abstract][Full Text] [Related]
15. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
16. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.
Kamat AM; Willis DL; Dickstein RJ; Anderson R; Nogueras-González G; Katz RL; Wu X; Barton Grossman H; Dinney CP
BJU Int; 2016 May; 117(5):754-60. PubMed ID: 26032953
[TBL] [Abstract][Full Text] [Related]
17. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
[TBL] [Abstract][Full Text] [Related]
18. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
[TBL] [Abstract][Full Text] [Related]
19. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.
Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H
Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552
[TBL] [Abstract][Full Text] [Related]
20. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
Packiam VT; Richards J; Schmautz M; Heidenreich A; Boorjian SA
Curr Opin Urol; 2021 May; 31(3):178-187. PubMed ID: 33742981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]